The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

40 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Protective effect of novel substituted nicotine hydrazide analogues against hypoxic brain injury in neonatal rats via inhibition of caspase.EBI
The Fifth Affiliated Hospital of Guangzhou Medical University
Synthesis and evaluation of N-acyl-substituted 1,2-benzisothiazol-3-one derivatives as caspase-3 inhibitors.EBI
TBA
Synthesis of 7-halogenated isatin sulfonamides: nonradioactive counterparts of caspase-3/-7 inhibitor-based potential radiopharmaceuticals for molecular imaging of apoptosis.EBI
Westf£Lische Wilhelms-Universit£T M£Nster
1,2-benzisothiazol-3-one derivatives as a novel class of small-molecule caspase-3 inhibitors.EBI
Tianjin University of Science and Technology
Influence of 4- or 5-substituents on the pyrrolidine ring of 5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin derivatives on their inhibitory activities towards caspases-3 and -7.EBI
Westf£Lische Wilhelms-Universit£T M£Nster
Synthesis, 18F-radiolabeling, and in vivo biodistribution studies of N-fluorohydroxybutyl isatin sulfonamides using positron emission tomography.EBI
Westf£Lische Wilhelms-Universit£T M£Nster
Synthesis of new fluorinated, 2-substituted 5-pyrrolidinylsulfonyl isatin derivatives as caspase-3 and caspase-7 inhibitors: nonradioactive counterparts of putative PET-compatible apoptosis imaging agents.EBI
Westf£Lische Wilhelms-Universit£T M£Nster
Irreversible inhibitors of cysteine proteases.EBI
Dart Neuroscience
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI
University of Florida
Dipeptidyl aspartyl fluoromethylketones as potent caspase-3 inhibitors: SAR of the P2 amino acid.EBI
Maxim Pharmaceuticals
Synthesis and evaluation of isatin analogs as caspase-3 inhibitors: introduction of a hydrophilic group increases potency in a whole cell assay.EBI
Washington University
Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study.EBI
University of Lisbon
Fluorinated isatin derivatives. Part 2. New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis.EBI
Westfalische Wilhelms-Universitat
Fluorinated isatin derivatives. Part 1: synthesis of new N-substituted (S)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatins as potent caspase-3 and -7 inhibitors.EBI
WestfäLische Wilhelms-UniversitäT
Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide.EBI
Imperial College
Structure-based discovery of a novel non-peptidic small molecular inhibitor of caspase-3.EBI
Tokyo University of Science
Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P(2) amino acid by 2-aminoaryl acids and other non-natural amino acids.EBI
Epicept
Isatin sulfonamide analogs containing a Michael addition acceptor: a new class of caspase 3/7 inhibitors.EBI
Washington University
Solid-phase analogue synthesis of caspase-3 inhibitors via palladium-catalyzed amination of 3-bromopyrazinones.EBI
Merck Frosst Centre For Therapeutic Research
Synthesis of novel caspase inhibitors for characterization of the active caspase proteome in vitro and in vivo.EBI
University of Edinburgh
5-pyrrolidinylsulfonyl isatins as a potential tool for the molecular imaging of caspases in apoptosis.EBI
University Hospital of The WestfäLische Wilhelms-UniversitäT
Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis.EBI
Washington University
Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P2 alpha-amino acid by a alpha-hydroxy acid.EBI
Maxim Pharmaceuticals
Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.EBI
Merck Frosst Centre For Therapeutic Research
Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group.EBI
Maxim Pharmaceuticals
Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization.EBI
Idun Pharmaceuticals
Acyl dipeptides as reversible caspase inhibitors. Part 1: initial lead optimization.EBI
Idun Pharmaceuticals
Caspases as targets for anti-inflammatory and anti-apoptotic drug discovery.EBI
Basf Bioresearch
In vitro characterization of [3H]MethoxyPyEP, an mGluR5 selective radioligand.BDB
Merck Research Laboratories
Molecular cloning and characterization of a new receptor for galanin.BDB
Merck Research Laboratories
The molecular interactions of buspirone analogues with the serotonin transporter.BDB
National Medicines Institute
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.BDB
National Taiwan University
Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.BDB
Irbm/Merck Research Laboratories
Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.BDB
Targegen
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .BDB
Piramed Pharma
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. Part 4: Heterocycles at C3.BDB
Bristol-Myers Squibb